$BSX News

BSX Q2 Deep Dive: WATCHMAN and Electrophysiology Challenges Temper Growth Outlook

Argus Research Downgrades Boston Scientific (BSX)

Argus Research Downgrades Boston Scientific to Hold

UBS Maintains Buy on Boston Scientific, Lowers Price Target to $67

Boston Scientific Lowered Full-Year Guidance on Headwinds in Electrophysiology, Watchman Portfolios, RBC Says

Citigroup Maintains Buy on Boston Scientific, Lowers Price Target to $61

BSX Q2 Earnings Call Highlights WATCHMAN and EP Pressure

RBC Capital Maintains Outperform on Boston Scientific, Lowers Price Target to $70

TD Cowen Maintains Buy on Boston Scientific, Lowers Price Target to $56

Canaccord Genuity Maintains Buy on Boston Scientific, Lowers Price Target to $66

Truist Securities Maintains Buy on Boston Scientific, Lowers Price Target to $57

What Are Wall Street Analysts' Target Price for Boston Scientific Stock?

Evercore ISI Group Maintains Outperform on Boston Scientific, Lowers Price Target to $55

Boston Scientific: Attempting The 2027 Reset

Wells Fargo Maintains Equal-Weight on Boston Scientific, Lowers Price Target to $50

Boston Scientific (BSX) Stock Sees Modest Fair Value Cut As Watchman Concerns Reset Expectations

Boston Scientific (BSX) Is Up 7.1% After Q2 Beat, Recall And Major Restructuring Plan - Has The Bull Case Changed?

Boston Scientific Corporation Q2 2026 Earnings Call Summary

Boston Scientific Q2 Earnings Call Highlights

Boston Scientific Corp (BSX) Q2 2026 Earnings Call Highlights: Strong Growth in Interventional ...